Alkermes Announces Topline Results of FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 in Major Depressive Disorder

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. ACN
2. SPCX
3. NVDA
4. MSTR
5. MU
6. BAUFF
7. ICE
8. KR
9. APGE
10. ABBV

Go back to Alkermes Announces Topline Results of FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 in Major Depressive Disorder
ALKERMES (NASDAQ: ALKS) Delayed: 44.99 --0 (-0%)
Previous Close $44.99    52 Week High $80.71 
Open $44.99    52 Week Low $27.14 
Day High $44.99    P/E 346.08 
Day Low $44.99    EPS $0.13 
Volume 3,598